

## Test Report: Standard Test Method for Efficacy of Antimicrobial Agents against Viruses in Suspension using Feline Leukaemia Virus

### Test Laboratory

### BluTest Laboratories Ltd

Robertson Incubator (Level 4)  
Robertson Building  
56 Dumbarton Road  
Glasgow, G11 6NU

### Identification of sample

Name of the product  
Manufacturer

#### SAFE 4

Safe Solutions Ltd, Wharton Green House, Bostock, Winsford,  
Cheshire, CW7 3BD  
10 February 2006  
Room temperature and darkness  
Not Known

Date of Delivery  
Storage conditions  
Active substances

### Test Method and its validation

Method

SAFE4 was diluted and 0.8 ml mixed with 0.2 ml virus suspension (DMEM + 5% FBS) and 0.1 ml sterile distilled water  
Virus CPE detected by antibody staining  
Dulbecco's modified Eagles medium + 5% v/v foetal bovine serum at 4°C

Dilution-neutralization  
Neutralizer

### Experimental Conditions


Period of analysis  
Product diluent used  
Product test concentrations  
Contact times  
Test temperature  
Interfering substance  
Stability of mixture  
Temperature of incubation  
Identification of virus

7 – 12 August 2006  
Sterile Hard Water  
1.0 % V/V; 2.0 % V/V; 5.0% V/V  
5 minutes ± 10s;  
20°C ± 1°C  
0.6 g/l foetal bovine serum  
Precipitate absent throughout the test  
37°C ± 1°C + 5% CO<sub>2</sub>  
Feline Leukaemia virus ATCC VR - 717 (FEA cells)

### Conclusion

SAFE 4 retains virucidal activity at 5 minutes contact, at 1 % V/V, (reduction in viral viability, 3.50 Log<sub>10</sub>) contact at 20°C under clean conditions (0,6 g/L protein as foetal bovine serum) for suspensions of Feline Leukaemia Virus (ATCC VR – 717).

Signed



Dr Chris Woodall  
Director, BluTest Laboratories Ltd  
Glasgow, UK  
24 June 2010

## FELINE LEUKAEMIA VIRUS

SAFE 4 CONCENTRATION	Contact time.	Log <sub>10</sub> reduction in virus viability (mean of 2 samples, 2 replicates/sample)
1.0 % V/V	5 minutes	3.50 = PASS*
2.0 % V/V	5 minutes	3.50 = PASS*
5.0 % V/V	5 minutes	3.50 = PASS*

\* This is the maximum achievable log<sub>10</sub> reduction for this virus when detection is limited by a residual cytotoxicity of log<sub>10</sub> 3.5 and is therefore recorded as a PASS.

<b>Controls</b>	
CELL CULTURE	Cell death was not observed. Antibody staining was not observed (2 replicates/sample controlled for each sample).
CYTOTOXICITY	Cytotoxicity was not observed at a greater dilution than 10 <sup>-2</sup> . This restricts the sensitivity of the assay to <3.5 Log <sub>10</sub> . TCID <sub>50</sub> units/ml (2 samples, 2 replicates/sample)

### DISCLAIMER

BluTest (BT) has performed the Testing detailed in this report using reasonable skill and care and that BT has used reasonable endeavors to carry out the Testing. All forecasts, recommendations and results contained in any report to the Company shall be submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the Testing or the use(s) to which any results or deliverables produced in the course of the Testing are or may be put by the Company or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the Testing can be achieved or (iii) that the Company can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Company will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Company may suffer directly or indirectly as a result of or in connection with: (i) the performance of the Testing, except for direct loss arising from a breach of the foregoing warranties; (ii) the use of any materials, samples or other information provided by the Company for use in the Testing; and (iii) the Company's reliance upon or use of any results or deliverables provided as part of the Testing. The total liability of BT shall not exceed the sums paid to BT for the performance of the Testing.